Literature DB >> 2283258

Preclinical profile of Gd-BOPTA. A liver-specific MRI contrast agent.

G Vittadini1, E Felder, C Musu, P Tirone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2283258     DOI： 10.1097/00004424-199009001-00028

Source DB:  PubMed          Journal:  Invest Radiol        ISSN： 0020-9996            Impact factor:   6.016


× No keyword cloud information.
  2 in total

1.  Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

Authors:  C S Peña; S Saini; R L Baron; B A Hamm; G Morana; R Caudana; A Giovagnoni; A Villa; A Carriero; D Mathieu; M W Bourne; M A Kirchin; G Pirovano; A Spinazzi
Journal:  Korean J Radiol       Date:  2001 Oct-Dec       Impact factor: 3.500

2.  The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives.

Authors:  Mark Woods; Peter Caravan; Carlos F G C Geraldes; Matthew T Greenfield; Garry E Kiefer; Mai Lin; Kenneth McMillan; M Isabel M Prata; Ana C Santos; Xiankai Sun; Jufeng Wang; Shanrong Zhang; Piyu Zhao; A Dean Sherry
Journal:  Invest Radiol       Date:  2008-12       Impact factor: 6.016
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.